Mary‑Dell Chilton, the NC biochemist who helped create the first genetically modified plants, died at 87 in Carrboro. Her work underpins modern crop biotechnology.

Duke and other labs are testing drugs and mitochondrial therapies that could ease chronic pain without sparking opioid addiction.

Duke researchers say a catheter‑delivered gene therapy restored pumping power and cut arrhythmias in lab‑grown heart tissue and monkeys, suggesting a possible one‑shot treatment for heart‑attack damage.

Asensus Surgical plans phased cuts of 108 employees at its Morrisville facility beginning Aug. 15; the company called the move an organizational realignment.

Altaris will buy RTP‑based Simulations Plus for about $375M, taking the drug‑development software company private while pledging to keep its headquarters in the Triangle.

Raleigh advisory firm Opex bought Dallas-based Intellys and says it will expand rapidly — including plans to roughly double its size — as it builds a national technology-advisory platform.

Red Hat and IBM launched Project Lightwell, a $5B initiative pairing AI and thousands of engineers to hunt and patch open-source vulnerabilities. The effort spotlights Raleigh's tech role.

N.C. A&T won approval to offer a Ph.D. in bioengineering — the first standalone doctorate of its kind at an HBCU — as the university pushes toward Carnegie R1 status.

A Duke-led study suggests bedside retinal scans of very preterm infants may predict motor and cognitive delays by age two.

Humacyte cut roughly 25% of its staff as it trims spending and refocuses commercial efforts for Symvess while preparing for upcoming trial data.

Ukrainian surgeons told Fort Bragg medics that drone swarms are stretching evacuations from minutes to days, forcing new training and underground care plans.

Corning says three new U.S. plants and more than 3,000 jobs will follow a multiyear partnership with Nvidia; the deal includes warrants that could lead to a multi‑billion dollar investment.

Duke researchers trained an AI on routine health records and say it can predict ADHD risk by age 5; the model shows strong accuracy but needs clinical validation.